Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study
- PMID: 2138908
- DOI: 10.1016/0277-5379(90)90296-6
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study
MeSH terms
Substances
LinkOut - more resources
Medical